Our immune system has developed targeted responses to different types of infections and other diseases over millions of years. We are developing an assay to rapidly measure this immune response using proprietary machine-learning algorithms to generate clinically actionable results. Faster diagnostics may support faster and smarter care decisions, and better patient outcomes.
Validated in numerous independent cohorts involving thousands of patients and published in leading medical journals, Inflammatix is developing an innovative point-of-care platform and test to aid in the diagnosis of acute infection and sepsis by measuring the patient’s immune response to bacteria and viruses.
Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Our tests are addressing significant clinical needs in acute infection and sepsis diagnosis that affect millions of people
Products in development, not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Based on US CDC numbers. Numbers also referenced from Martin, NEJM 2003; Donnelly, Antimicrob. Ag Chemo 2013; Hasegawa, PIDJ 2015; Goto, J Am Ger Soc 2016; Magill, NEJM 2014; Horeczko, West JEM 2014; Fleming-Dutra, JAMA 2016.
In the News
Recent notable news stories
Do Your Genes Know What’s Making You Sick?
January 6, 2022
Artificial Intelligence for Clinical Decision Support in Sepsis
May 13, 2021
Inflammatix Checks off All the Right Boxes with Investors
March 19, 2021
Inflammatix nets $102M to advance its immune system tests for infectious diseases
Inflammatix is reimagining diagnostics by developing rapid tests that read the immune system to resolve major clinical and public health challenges. Our initial focus is on acute bacterial and viral infections, and sepsis.
We’re seeking teammates with expertise, curiosity and passion for solving clinical challenges with a focus on patient outcomes. If that sounds like you, check out our Careers Page.